Skip to main content

Alzheimer’s Disease- Roche (GRADUATE)

 

The primary objective of this study is to slow cognitive and functional impairment in participants with early (mild or prodromal) Alzheimer’s disease.

Phase: 3

Age: 50 to 90 years of age

Indication: Mild Cognitive Impairment due to Alzheimer’s disease

Category: Treatment

For more information: https://clinicaltrials.gov/ct2/show/NCT02477800

Studies Currently Available At

Sign Up For This Study